Vitamin K2 MK-7.

Vitamin D drives expression of osteocalcin and matrix Gla protein while vitamin K carries out the gamma-carboxylation that switches them on. One makes the protein, the other activates it.

Carboxylated Gla residues are the calcium binding sites on osteocalcin and matrix Gla protein. Vitamin K therefore governs where supplemental calcium is held rather than how much is absorbed.

Magnesium is required to hydroxylate vitamin D into its active form and is a structural part of the bone mineral itself. It sits between the D and K steps in practice.

Phylloquinone clears quickly and is taken up mainly by the liver, while MK-7 has a long half life and reaches bone and vessel tissue. Together they cover both compartments of the same cycle.

High-dose alpha-tocopherol interferes with vitamin K recycling and can lower gamma-carboxylation. It works against the exact step MK-7 is dosed to support.

MK-7 is a fat-soluble quinone that needs dietary lipid and bile to form absorbable micelles. Oil-filled delivery raises uptake against a dry tablet taken without food.

Menaquinones and ubiquinone are both prenylated quinones whose side chains come off the same isoprenoid pool, and the enzyme UBIAD1 that prenylates vitamin K also participates in that pool. Both are lipid-soluble and absorbed with dietary fat by the same route. The overlap is biochemical rather than a demonstrated combined effect.

Ubiquinol formulations are oil-suspended for the same reason MK-7 is, since both need a lipid phase to be taken up in the small intestine. Co-formulating them in one softgel is a practical absorption decision. It is a formulation rationale, not an efficacy claim.

Menaquinone-7 is highly lipophilic and its uptake depends on incorporation into mixed micelles, which requires bile and dietary fat. Taking it with an oil-containing meal or an oil-based capsule raises the absorbed fraction relative to a fat-free dose. This is standard fat-soluble vitamin handling.

Phospholipid emulsifiers disperse MK-7 into fine droplets that enter micelles more readily, which is why lecithin appears in oil-suspension and powder MK-7 formats. The role is delivery, not activity. It does not change what the vitamin does once absorbed.

Ascorbate is the cofactor for prolyl and lysyl hydroxylases that build the collagen scaffold of bone, while vitamin K carboxylates osteocalcin, the protein that binds that scaffold to mineral. One handles the organic matrix and the other the protein that links matrix to mineral. Trials of vitamin K on bone turnover markers have not isolated a vitamin C contribution.

Boron influences calcium and magnesium retention and the metabolism of steroid hormones involved in bone turnover, while MK-7 acts through carboxylation of osteocalcin and matrix Gla protein. The two touch bone through separate mechanisms. No combination trial supports a joint effect.

Zinc is required for alkaline phosphatase and for collagen-processing enzymes in bone tissue, a different node from vitamin K-dependent carboxylation. Formulations pair them for that reason. The pairing is mechanistic rather than trial-backed.

Manganese is a cofactor for enzymes that assemble the proteoglycan components of bone and cartilage matrix. Vitamin K acts on the Gla proteins that regulate where mineral is deposited. The two contribute to different steps of the same tissue.

Silicon is associated with collagen cross-linking and early bone matrix formation in observational and animal work, while MK-7 governs carboxylation of matrix Gla protein. Human evidence for silicon here is associative, not causal. The pairing is a matrix-plus-mineral-handling argument.

Strontium substitutes for calcium in the hydroxyapatite lattice and is incorporated into bone mineral, and it also interferes with densitometry readings because it is denser than calcium. Vitamin K acts on the proteins that direct mineral placement rather than on the mineral itself. Strontium and calcium also compete for absorption, so timing matters.

Hydroxyapatite is a calcium phosphate, so phosphate is a structural requirement for mineral deposition, while vitamin K-dependent osteocalcin and matrix Gla protein regulate where that mineral goes. Neither substitutes for the other. Phosphate intake is usually ample from ordinary food.

Retinol, vitamin K, vitamin D and vitamin E all require bile salt micelles for uptake and can compete for micellar capacity when large doses arrive together. Retinol also influences osteoblast activity independently. In practice this argues for moderate co-doses rather than avoidance.

High intakes of tocopherol and tocotrienol isomers can lower vitamin K status, through competition at absorption and through effects on vitamin K metabolism and clearance. The interaction becomes relevant at supplemental rather than dietary amounts. Where both are taken, spacing and moderate dosing are the practical response.

Gut bacteria synthesise a range of menaquinones, and the human colon carries a bacterial menaquinone pool distinct from dietary intake. How much of that pool is absorbed remains uncertain because absorption in the colon is limited. A probiotic therefore adds an unquantified and probably small contribution alongside a defined MK-7 dose.

Fermentable fibre feeds the colonic community that synthesises bacterial menaquinones. Whether that translates into a measurable change in circulating vitamin K status has not been established. The reasoning is upstream of any human measurement.

Natto fermentation produces both MK-7 and the fibrinolytic enzyme nattokinase, which is why they appear together in products derived from the same broth. Vitamin K is the cofactor for carboxylating clotting factors, while nattokinase acts on fibrin breakdown, so their influences on coagulation run in opposite directions. Anyone whose clotting is being monitored should keep intake of both steady and discuss changes with their clinician.

Collagen forms the organic scaffold on which bone mineral is laid down, and osteocalcin, once carboxylated by vitamin K, binds that mineral to the scaffold. Trials of vitamin K report changes in carboxylation status and bone turnover markers rather than in collagen itself. Markers of turnover are not the same as a fracture outcome.